<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603445</url>
  </required_header>
  <id_info>
    <org_study_id>CBCL201X2102C</org_study_id>
    <nct_id>NCT02603445</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL</brief_title>
  <official_title>A Phase Ib Dose Escalation Study of BCL201 in Combination With Idelalisib in Patients With Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ib multi-center, open-label study: escalation part followed by expansion&#xD;
      part. The primary purpose of the Phase Ib CBCL201X2102C study is to characterize the safety&#xD;
      and tolerability of BCL201 combined with idelalisib in patients with FL and MCL.&#xD;
&#xD;
      Approximately 65 patients are to be enrolled.&#xD;
&#xD;
      The primary endpoint for the Phase Ib is frequency, severity and seriousness of AEs, lab&#xD;
      abnormalities and other safety parameters such as ECG changes. An adaptive Bayesian logistic&#xD;
      regression model (BLRM) will guide the dose escalation to determine the MTD/RDE in phase Ib.&#xD;
      In addition Bayesian regression models will be used to estimate the dose-exposure&#xD;
      relationships for both BCL201 and idelalisib in order to guide the escalation steps. A&#xD;
      Bayesian method for the expansion part will be used for the primary activity objective.&#xD;
&#xD;
      The study data will be analyzed and reported based on all patients' data of the escalation&#xD;
      and expansion part.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2015</start_date>
  <completion_date type="Actual">July 10, 2018</completion_date>
  <primary_completion_date type="Actual">July 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Characterized by Frequency, severity and seriousness of AEs, lab abnormalities and other safety parameters such as electrocardiogram (ECG) changes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of dose limiting toxicities (DLTs)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure to BCL201 and idelalisib as measured by AUC0-24h at C1D15</measure>
    <time_frame>Cycle = 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of BCL201, idelalisib and GS-563117 (metabolite of idelalisib)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC pharmacokinetics (PK) parameter for BCL201, idelalisib and GS-563117</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response (PR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable disease (SD)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax pharmacokinetics (PK) parameter for BCL201, idelalisib and GS-563117</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Follicular Lymphoma, Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Follicular lymphoma (FL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mantle cell lymphoma (MCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCL201</intervention_name>
    <arm_group_label>Follicular lymphoma (FL)</arm_group_label>
    <arm_group_label>Mantle cell lymphoma (MCL)</arm_group_label>
    <other_name>S55746</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <arm_group_label>Follicular lymphoma (FL)</arm_group_label>
    <arm_group_label>Mantle cell lymphoma (MCL)</arm_group_label>
    <other_name>Idela</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of FL or MCL according to WHO 2008&#xD;
&#xD;
          -  Relapsed or refractory with at least one (FL) or two (MCL), but not more than four,&#xD;
             prior lines of antineoplastic regimens.&#xD;
&#xD;
          -  Either FDG-avid on FDG-PET or measurable disease by CT on cross sectional imaging: &gt;&#xD;
             1.5 cm for nodal lesion, &gt; 1.0 cm for extra nodal lesion.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For dose escalation part: Patients with MCL at high risk for tumor lysis syndrome&#xD;
&#xD;
          -  Prior treatment with PI3Kδ or Bcl-2 inhibitors.&#xD;
&#xD;
          -  Any other malignant disease&#xD;
&#xD;
          -  History of serious allergic reactions including anaphylaxis and toxic epidermal&#xD;
             necrolysis&#xD;
&#xD;
          -  Inadequate organ function&#xD;
&#xD;
          -  Concomitant treatment with:&#xD;
&#xD;
          -  Strong CYP3A4/5 inducers or inhibitors&#xD;
&#xD;
          -  Sensitive CYP3A4/5 substrates or CYP3A4/5 substrates with narrow therapeutic index&#xD;
             (NTI)&#xD;
&#xD;
          -  Sensitive CYP2D6 substrates or CYP2D6 substrates with NTI&#xD;
&#xD;
          -  Selected dual substrates of CYP3A4/5 and CYP2C8&#xD;
&#xD;
          -  Selected dual substrates of CYP3A4/5 and CYP2D6&#xD;
&#xD;
          -  Selected dual substrates of OATP and CYP450&#xD;
&#xD;
          -  Selected dual substrates of CYP3A4/5 and P-gp&#xD;
&#xD;
          -  NTI P-gp substrates&#xD;
&#xD;
          -  QT prolonging drugs with a known risk to induce TdP&#xD;
&#xD;
          -  Proton pump inhibitors&#xD;
&#xD;
          -  Treatment by warfarin or equivalent vitamin K antagonists.&#xD;
&#xD;
          -  Other investigational therapies&#xD;
&#xD;
          -  Herbal preparations/ medications&#xD;
&#xD;
          -  Grapefruit, Seville oranges or products containing either juice&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCL201</keyword>
  <keyword>idelalisib</keyword>
  <keyword>Follicular lymphoma</keyword>
  <keyword>FL</keyword>
  <keyword>mantle cell lymphoma</keyword>
  <keyword>MCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

